目的 探究酒石酸美托洛尔联合辛伐他汀治疗的临床疗效。方法 对我院2013年2月—2014年5月间收治的80例心律失常患者的临床资料进行回顾性分析,将80例患者随机划分为研究组与对照组,两组各40例;对照组40例心律失常患者给予酒石酸美托洛尔治疗,研究组在对照组的治疗基础上给予辛伐他汀治疗,比较研究组患者与对照组患者的临床治疗效果。结果 研究组患者临床治疗总有效率高于对照组,两组差异有统计学意义(P＜0.05);研究组患者室性期前收缩次数、房性期前收缩次数低于对照组,两组差异有统计学意义(P＜0.05);研究组患者与对照组患者不良反应发生例数无统计学意义(P＞0.05)。结论 心律失常行辛伐他汀治疗的临床疗效显著,值得临床推广应用。

目的 观察改良INP方案对肺腺癌伴有脑转移患者的临床疗效及毒副作用,并探讨该方案疗效与Ⅲ型β微管蛋白(β-tubulin-Ⅲ)在肺癌组织中表达水平的关系。方法 收集2010年4月—2013年1月广州医科大学附属第一医院胸外科收治的15例肺腺癌伴有脑转移患者的临床资料。所有患者均采用改良INP方案治疗,使用RECIST 1.0标准进行判定。结果 脑转移瘤取得CR 1例(1/15),PR 5例(5/15),SD 4例(4/15),PD 5例 (5/10),该方案对脑转移瘤的总缓解率(overall response rate,ORR)为40%,疾病控制率(disease control rate,DCR)达66.7%,毒副作用轻度可控;Ⅲ型β微管蛋白低表达对该方案的疗效有优于高表达的趋势。结论 肺腺癌伴有脑转移患者采用改良INP方案进行化疗,脑转移瘤临床疾病控制率较高,耐受性良好;肿瘤组织β-tubulin-Ⅲ表达水平可能与该方案的疗效相关。

Objective To investigate the efficacy and toxicity of chemotherapy of modified INP regimen in the treatment of adenocarcinoma with brain metastases. At the same time,to explore the relationship between expression of β-tubulin-Ⅲ in NSCLC biopsies and sensitivity to this modified INP regimen. Methods The clinical data of 15 adenocarcinoma with brain metastases patients who had been admitted to the first affiliated hospital of Guangzhou medical university from April 2010 to January 2013 were retrospectively analyzed. All patients received modified INP regimen.RECIST 1.0 was taken to know the result. Results For brain metastasis of the 15 patients, complete response (CR) and partial response(PR) were 1 and 5 patients, respectively. 4 patients were stable disease (SD) and progression disease(PD) in 5 patients. The overall response rate(ORR) was 40% and the disease control rate(DCR) was 66.7%. The toxicity was mild. Furthermore, we found NSCLC patients with low β-tubulin-Ⅲexpression had better ORR than those with high expression. Conclusion The modified INP regimen is effective and well-tolerable for brain metastases of adenocarcinoma. The β-tubulin-Ⅲ expression may be associated with the efficacy of this regimen.

目的 探讨莫西沙星结合抗结核药物治疗糖尿病合并肺结核患者的临床疗效分析。方法 将本组126例糖尿病合并肺结核患者分为对照组(n=63)和观察组(n=63);对照组给予降血糖治疗及抗结核药物降糖治疗,观察组在对照组治疗基础上服用莫西沙星;两组治疗均以3个月为一个疗程,2个疗程后统计疗效。结果 观察组总有效率(93.65%)高于对照组(76.19%),差异有统计学意义(P<0.05);观察组痰菌检测转阴率(94.59%)高于对照组(79.49%),差异有统计学意义(P<0.05);治疗过程中观察组与对照组出现不良反应情况相比较差异无统计学意义(P＞0.05)。结论 莫西沙星结合抗结核药物治疗糖尿病合并肺结核疗效显著,具有较强的杀菌作用。

Objective To investigate the clinical efficacy of moxifloxacin combining with antituberculosis drug in the treatment of diabetic patients with pulmonary tuberculosis. Methods A group of 126 patients of diabetes complicated with pulmonary tuberculosis were divided into control group (n=63) and observation group (n=63); the control group was given by hypoglycemic therapy and therapy of antituberculosis drug only, and the observation group was also given by moxifloxacin; two groups were treated for 3 months as a course.The clinical efficacy was evaluated after 2 courses. Results The total effective rate of observation group (93.65%) was significantly higher than that of the control group (80.95%), and the difference was statistically significant (P<0.05); the negative sputum rate of observation group (94.59%) was higher than that of the control group (79.49%), and the difference was statistically significant (P<0.05); there was no statistically significant difference between the observation group and the control group in adverse effects. Conclusion The curative effect of moxifloxacin combining with antituberculosis drug in the treatment of diabetes mellitus complicated with pulmonary tuberculosis was good, with strong bactericidal effect.

目的 观察有创-无创序贯通气治疗慢性阻塞性疾病(COPD)急性加重并呼吸衰竭的疗效。方法 选取2013年3月—2015年3月在兴宁市人民医院呼吸科收治的COPD急性加重并II型呼吸衰竭、需行机械通气的患者80例,随机进行有创-无创序贯通气治疗组A和单一有创通气治疗组B,两组除了机械通气的方式不同之外,其他的常规治疗均相同,主要观察两组患者进行相关机械通气方式前后的呼吸、循环及血气指标的变化情况以及进行机械通气的总时间和住院时间及呼吸机相关肺炎(VAP)的发生例数。结果 治疗组患者的血气、呼吸及循环内的各项生化指标改善程度均与对照组无统计学意义(P>0.05),同时治疗组患者的VAP的发生率,总的住院时间,进行机械通气的总时间少于对照组患者,有统计学意义(P<0.05)。结论 采用有创-无创序贯通气治疗慢性阻塞性疾病(COPD)急性加重并呼吸衰竭综合治疗效果要好于采用单一有创通气治疗,值得临床推广应用。